Pay in 4 interest-free payments of $20.00 Learn more
Ships within 48 hours · Estimated delivery Jul 25 - Jul 30
Inhibition of PAI-1 via PAI-039 improves dermal wound closure in diabetes mellitus
All LGK974-sensitive pancreatic cancer cell lines carried inactivating mutations of RNF43
10-24-12-21-11-22-24)16-4-3-15(19)9-17(16)20/h3-4
CRISPR-mediated targeting of HER2 inhibits cell proliferation through a dominant negative mutation
Tipiracil Hydrochloride Catalog No.:M9551-10 Inhibition of PAI-1 via PAI-039Tipiralacil, also known as TPI, is a thymidine phosphorylase inhibitor (TPI). Tipiracil is one of the active components in TAS 102, which is an anticancer drug candidate currently in clinical trials. TAS 102 consists of the cytotoxin Trifluridine and the thymidine phosphorylase inhibitor (TPI) tipiracil. Trifluridine is incorporated into DNA during DNA synthesis and inhibits tumor cell growth. Tipiracil protects trifluridine from being broken down